Moderna wins FDA approval for new flu vaccine targeting older adults

Moderna has received approval from the US Food and Drug Administration (FDA) for its new flu vaccine mFLUSIVA, which is designed for use in adults aged 50 and over. The clearance marks an important step for the pharmaceutical company as it diversifies its vaccine portfolio beyond Covid-19. The mFLUSIVA vaccine represents Moderna’s effort to apply its messenger RNA (mRNA) technology platform to seasonal influenza prevention. This approval allows Moderna to compete in the established flu vaccine market, which is particularly important given the vulnerable nature of older populations when it comes to influenza-related complications. The vaccine will now be available for eligible adults in the United States, offering an additional option alongside existing flu vaccination programmes that typically recommend annual shots for people aged 50 and above.

Source: Walla News — Original article in Hebrew.